Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 3,019 matching trials from the live ClinicalTrials.gov search.
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bryostatin-1, Paclitaxel (Taxol)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Houston, Texas
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus

NCT00903136
Conditions
Esophageal Cancer, Precancerous Condition
Interventions
questionnaire administration, comparison of screening methods, diagnostic endoscopic procedure, esophagogastroduodenoscopy, tethered capsule endoscopy
Other · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Conditions
Brain Cancer, Lung Cancer (Diagnosis), Renal Cancer
Interventions
Digital Pathology Evaluation
Diagnostic Test
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
Interventions
Registry - Observational
Device
Lead sponsor
RefleXion Medical
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Duarte, California • Palo Alto, California • New Haven, Connecticut + 2 more
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
Irinotecan, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Esophageal Cancer
Interventions
Itraconazole
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Terminated Phase 2Phase 3 Interventional Results available

Prevention of Post-operative Pneumonia (POPP)

NCT01446874
Conditions
Post-operative Pneumonia, Lung Cancer, Esophageal Cancer
Interventions
0.12% chlorhexidine solution
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma
Interventions
Gabapentin, Ketamine
Drug
Lead sponsor
Natalie Lockney
Other
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Not applicable Interventional Results available

Staging of Superficial EAC Using VLE

NCT03385343
Conditions
Esophageal Cancer
Interventions
VLE imaging for staging EAC
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Carcinoma, Squamous Cell
Interventions
paclitaxel poliglumex, cetuximab, radiation therapy (IMRT or 3D-CRT)
Drug · Biological · Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
Terminated Phase 2 Interventional Results available

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

NCT02875613
Conditions
Nasopharyngeal Cancer
Interventions
Avelumab
Drug
Lead sponsor
Assuntina Sacco, M.D.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
La Jolla, California • Boston, Massachusetts
Conditions
Advanced Solid Tumor
Interventions
hSTC810
Biological
Lead sponsor
STCube, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Conditions
Esophageal Cancer, Lung Cancer
Interventions
Interactive Voice Response System, Symptoms Report
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Head and Neck Cancer
Interventions
MRI and PET imaging
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Thyroid Neoplasms
Interventions
AG013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Conditions
Thyroid Carcinoma
Interventions
CellFX nsPFA Percutaneous Electrode System
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Sarasota, Florida • Houston, Texas
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Conditions
Head and Neck Cancer
Interventions
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Combination Product · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
Conditions
Head and Neck Cancer
Interventions
gene therapy, interleukin-2 gene, methotrexate
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida